Medpace (NASDAQ:MEDP) Trading Up 1.2%

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) were up 1.2% on Monday . The company traded as high as $401.99 and last traded at $400.82. Approximately 27,821 shares were traded during trading, a decline of 89% from the average daily volume of 248,000 shares. The stock had previously closed at $395.93.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Medpace in a research note on Monday, March 18th. They issued a "hold" rating and a $395.00 target price on the stock. Jefferies Financial Group upgraded Medpace from a "hold" rating to a "buy" rating and boosted their target price for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. UBS Group upgraded Medpace from a "neutral" rating to a "buy" rating and boosted their target price for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. StockNews.com upgraded Medpace from a "hold" rating to a "buy" rating in a research note on Tuesday, April 23rd. Finally, Robert W. Baird boosted their target price on Medpace from $446.00 to $454.00 and gave the company an "outperform" rating in a research note on Wednesday, April 24th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $443.00.

Medpace Stock Up 1.1 %

The business has a 50-day simple moving average of $398.00 and a two-hundred day simple moving average of $327.40. The company has a market cap of $12.40 billion, a price-to-earnings ratio of 40.80, a PEG ratio of 1.97 and a beta of 1.38.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping analysts' consensus estimates of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company had revenue of $511.00 million during the quarter, compared to analysts' expectations of $512.39 million. During the same quarter in the previous year, the firm earned $2.27 earnings per share. The business's quarterly revenue was up 17.7% compared to the same quarter last year. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Ashley M. Keating sold 250 shares of the business's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $409.87, for a total transaction of $102,467.50. Following the completion of the transaction, the director now owns 250 shares of the company's stock, valued at approximately $102,467.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Ashley M. Keating sold 250 shares of the business's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $409.87, for a total transaction of $102,467.50. Following the completion of the transaction, the director now owns 250 shares of the company's stock, valued at approximately $102,467.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the business's stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the transaction, the chief executive officer now directly owns 4,833,019 shares of the company's stock, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. Insiders sold 189,340 shares of company stock valued at $76,651,647 over the last quarter. Insiders own 20.30% of the company's stock.

Hedge Funds Weigh In On Medpace

Several large investors have recently made changes to their positions in the business. RiverPark Advisors LLC acquired a new position in Medpace in the 4th quarter valued at approximately $26,000. Contravisory Investment Management Inc. acquired a new position in Medpace in the 4th quarter valued at approximately $26,000. Rise Advisors LLC acquired a new position in Medpace in the 1st quarter valued at approximately $27,000. Mather Group LLC. acquired a new position in Medpace in the 1st quarter valued at approximately $28,000. Finally, FinTrust Capital Advisors LLC acquired a new position in Medpace in the 3rd quarter valued at approximately $30,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.